- Previous Close
5.67 - Open
5.75 - Bid 5.02 x 900
- Ask 5.70 x 4000
- Day's Range
5.24 - 5.75 - 52 Week Range
3.81 - 14.57 - Volume
15,287 - Avg. Volume
13,010 - Market Cap (intraday)
53.038M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.51 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
serinatherapeutics.comRecent News: SER
View MorePerformance Overview: SER
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SER
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SER
View MoreValuation Measures
Market Cap
53.04M
Enterprise Value
49.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
87.86
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-124.04%
Return on Equity (ttm)
-485.36%
Revenue (ttm)
56k
Net Income Avi to Common (ttm)
-11.14M
Diluted EPS (ttm)
-1.51
Balance Sheet and Cash Flow
Total Cash (mrq)
3.67M
Total Debt/Equity (mrq)
90.75%
Levered Free Cash Flow (ttm)
-7.94M